Physician profile
Robert L Deucher
NPI 1922042662
$3,041.42
in general payments reported to CMS, 2019-2025
34 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $340 · 2021: $403 · 2022: $593 · 2023: $634 · 2024: $271 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,014 · Education: $20.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.76 |
| Education | $20.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $539.95 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $377.41 | 2019-2024 | |
| Amgen INC. | $244.47 | 2019-2025 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $181.53 | 2019-2023 | |
| Radius Health, INC. | $170.76 | 2019-2025 | Tymlos |
| Lilly USA, LLC | $153.07 | 2019-2024 | Amyvid, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.77 | 2019-2023 | Jardiance |
| Idorsia Pharmaceuticals US INC | $114.39 | 2022-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $112.21 | 2023-2025 | Nuedexta, Rexulti |
| Astrazeneca Pharmaceuticals LP | $99.97 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $99.20 | 2019-2022 | |
| Amarin Pharma, INC. | $82.88 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.10 | 2023-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $60.04 | 2021-2023 | Verquvo, Belsomra |
| Abbott Laboratories | $53.32 | 2022-2023 | Freestyle Libre 2 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $53.01 | 2019 | |
| Insulet Corporation | $52.70 | 2023 | Omnipod |
| Janssen Pharmaceuticals, INC | $51.99 | 2019 | |
| Abbvie INC. | $50.52 | 2022-2023 | Vraylar |
| Corium, LLC | $46.87 | 2023 | Adlarity |
| Aytu Biopharma, INC. | $37.07 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $33.18 | 2023-2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $29.85 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $28.98 | 2021 | |
| Ironwood Pharmaceuticals, INC | $21.24 | 2022 | |
| Senseonics, Incorporated | $20.00 | 2020 | |
| Phadia US INC. | $18.24 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.19 | 2025 | Xifaxan |
| Exact Sciences Corporation | $16.69 | 2025 | The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $13.92 | 2024 | Veozah |
| Medtronic, INC. | $13.80 | 2022 | |
| Mylan Specialty L.P. | $13.23 | 2021 | |
| Nestle Healthcare Nutrition INC. | $12.48 | 2020 | |
| Daiichi Sankyo INC. | $12.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Deucher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.